Topline results from a Phase II study show SAGE-324, Sage Therapeutics’ investigational oral neuroactive steroid GABAA receptor positive allosteric modulator, significantly reduced tremor score in adult patients with essential tremor.
Immunosuppressive drugs for inflammatory diseases like rheumatoid arthritis, multiple sclerosis and ulcerative colitis can impair the body’s response to the Covid-19 vaccines from Pfizer/BioNTech and Moderna, according to new data.
Biogen bets on depression drug in $1.5 billion deal with Sage Therapeutics
Acquisitions, Analysts, Business, Charcot–Marie–Tooth Disease (CMT), Depression, Essential Tremor, Major Depressive Disorder (MDD), Milestone Payments, Neurological Disorders, Postpartum Depression, Potential Blockbusters, Product Pipeline, Shares, U.S. Centers for Disease Control and PreventionBiogen will take a $650 million stake in Sage Therapeutics and make an upfront payment of $875 million to jointly develop and sell treatments for depression and other neurological disorders.
Cambridge, Massachusetts-based Praxis Precision Medicines raised about $110 million in a Series C financing, led by Eventide Asset Management,
Jazz Pharmaceuticals plc announced the acquisition of clinical-stage biotechnology company Cavion Inc. through a merger with a Jazz subsidiary.